H. Roger Lijnen

H. Roger Lijnen's AcademicInfluence.com Rankings

H. Roger Lijnen

Chemistry

#3114

World Rank

#4104

Historical Rank

chemistry Degrees

H. Roger Lijnen

Biology

#8798

World Rank

#11930

Historical Rank

Molecular Biology

#1144

World Rank

#1170

Historical Rank

Biochemistry

#1300

World Rank

#1420

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Why Is H. Roger Lijnen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

H. Roger Lijnen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. (1982) (1286)
Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation (2001) (249)
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. (1979) (249)
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. (1980) (246)
Studies on the mechanism of the antifibrinolytic action of tranexamic acid. (1981) (219)
Angiogenesis and development of adipose tissue (2010) (213)
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. (1999) (211)
Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene (2002) (210)
On the mechanism of fibrin-specific plasminogen activation by staphylokinase. (1991) (195)
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. (1983) (194)
Mechanisms of physiological fibrinolysis. (1995) (182)
Activation of plasminogen by pro-urokinase. I. Mechanism. (1986) (182)
Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. (1984) (175)
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. (1986) (173)
Matrix Metalloproteinases and Cellular Fibrinolytic Activity (2004) (163)
Strategies for the Improvement of Thrombolytic Agents (1991) (160)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology (1984) (151)
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. (1984) (148)
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). (1987) (142)
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? (1994) (140)
Matrix Metalloproteinase System Deficiencies and Matrix Degradation (1999) (134)
Tissue‐type plasminogen activator: a historical perspective and personal account (2004) (134)
Basic and clinical aspects of fibrinolysis and thrombolysis. (1991) (132)
Effect of Retraction on the Lysis of Human Clots with Fibrin Specific and Non-Fibrin Specific Plasminogen Activators (1989) (123)
Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. (1999) (119)
Endothelium in hemostasis and thrombosis. (1997) (117)
Activation of plasminogen by pro-urokinase. II. Kinetics. (1986) (117)
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. (1987) (113)
Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. (1982) (107)
Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. (1979) (104)
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. (1986) (104)
The tissue-type plasminogen activator story. (2009) (101)
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). (1990) (101)
Characterization of the murine plasma fibrinolytic system. (1994) (101)
On the mechanism of the activation of human plasminogen by recombinant staphylokinase. (1993) (98)
Tissue-type plasminogen activator, a new prognostic marker in breast cancer. (1988) (95)
Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy (1995) (93)
Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. (2009) (91)
The fibrinolytic system in man. (1986) (90)
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. (1986) (89)
Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development (2001) (87)
A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. (1985) (85)
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). (1998) (83)
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. (1989) (82)
Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. (2005) (81)
Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis (1989) (78)
Dysfibrinogenemia (Fibrinogen Dusard) Associated with Impaired Fibrin-Enhanced Plasminogen Activation (1984) (78)
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. (1987) (77)
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. (1987) (76)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys (1984) (76)
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. (2005) (75)
Effect of matrix metalloproteinase inhibition on adipose tissue development. (2005) (71)
On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice (2005) (68)
Adipose Tissue and Atherothrombosis (2003) (68)
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. (1988) (68)
Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. (1986) (67)
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. (1996) (65)
Characterization of the interaction between plasminogen and staphylokinase. (1994) (65)
Isolation and characterisation of natural and recombinant staphylokinase (1992) (65)
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. (2000) (64)
Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. (1993) (63)
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. (1987) (63)
Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. (1984) (62)
Correlation between Progressive Adsorption of Plasminogen to Blood Clots and Their Sensitivity to Lysis (1990) (61)
Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis (1991) (61)
On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin. (1981) (61)
Multiple forms of plasminogen activator in human breast tumors. (1985) (60)
Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis1 (2006) (59)
Interactions between Staphylokinase, Plasmin(ogen), and Fibrin (1996) (59)
Effects of plasminogen activator inhibitor‐1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice (2005) (59)
Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro (1986) (58)
Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia coli-Induced Abdominal Sepsis in Mice1 (2006) (58)
Fibrinolytic Agents: Mechanisms of Activity and Pharmacology (1995) (57)
Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity (2012) (56)
Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. (1993) (54)
Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators (1991) (53)
Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. (1986) (52)
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. (1993) (52)
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories (2003) (51)
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. (1991) (50)
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. (1989) (50)
Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1989) (49)
Mechanisms of plasminogen activation (1994) (48)
Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems (2000) (48)
Histidine-rich glycoprotein in a normal and a clinical population. (1981) (48)
A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents (1990) (47)
Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. (1980) (47)
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques (2006) (46)
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. (1987) (46)
Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. (1993) (45)
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. (1993) (44)
On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin (1992) (44)
Biochemical-properties of natural and recombinant staphylokinase (1992) (44)
Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor. (1983) (43)
Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue (2006) (43)
Structural domains of streptokinase involved in the interaction with plasminogen. (1995) (43)
Impaired fibrinolysis and the risk for coronary heart disease. (1996) (42)
Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species (1984) (41)
Impaired Adipose Tissue Development in Mice With Inactivation of Placental Growth Factor Function (2006) (41)
New approaches to thrombolytic therapy. (1984) (41)
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. (1989) (41)
Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties. (1987) (40)
Pathophysiology of the plasminogen/plasmin system (1996) (39)
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura (2010) (39)
Structural and Functional Basis of Plasminogen Activation by Staphylokinase (1999) (39)
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. (1990) (39)
Amino‐acid sequence of human α2‐antiplasmin (1987) (37)
Characterization and Targeting of the Murine α2-Antiplasmin Gene (1997) (37)
Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. (1994) (37)
Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro (1992) (36)
Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase. (1984) (36)
Increased Angiostatin Levels in Bronchoalveolar Lavage Fluids from ARDS Patients and from Human Volunteers after Lung Instillation of Endotoxin (2002) (35)
Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. (1991) (34)
Interaction of staphylokinase with different molecular forms of plasminogen. (1993) (34)
Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. (1986) (33)
Histidine-Rich Glycoprotein Modulates the Anticoagulant Activity of Heparin in Human Plasma (1984) (33)
In Vitro Fibrinolytic Activity of Recombinant Tissue-Type Plasminogen Activator in the Plasma of Various Primate Species (1984) (33)
Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity (2002) (33)
Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. (1984) (33)
Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. (1987) (32)
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. (1990) (30)
Mechanisms of plasminogen activation by mammalian plasminogen activators. (1988) (30)
Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. (1986) (30)
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. (1988) (30)
Interaction of Heparin with Histidine-Rich Glycoprotein and with Antithrombin III (1983) (30)
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. (1986) (30)
Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model (1991) (29)
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. (1992) (29)
Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin‐induced cell detachment and apoptosis (2005) (29)
Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. (1993) (29)
Role of Active Center and Lysine Binding Sites of Plasmin in Plasmin-Induced Platelet Activation and Disaggregation (1991) (29)
Effect of Fibrin-Like Stimulators on the Activation of Plasminogen by Tissue-Type Plasminogen Activator (t-PA) - Studies with Active Site Mutagenized Plasminogen and Plasmin Resistant t-PA (1990) (29)
Age-associated adaptations in murine adipose tissues. (2010) (28)
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator. (1991) (28)
In vitro prothrombin synthesis from a purified precursor protein. III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin. (1981) (28)
Obesity promotes injury induced femoral artery thrombosis in mice. (2008) (27)
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. (1990) (26)
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1) (2004) (26)
Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase (1992) (26)
Enhanced Fibrinolytic Potential in Mice with Combined Homozygous Deficiency of α2-antiplasmin and PAI-1 (2001) (26)
A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. (1986) (26)
Neutralization of heparin activity by binding to human histidine-rich glycoprotein. (1983) (26)
Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor. (2008) (26)
Fibrin‐specific Fibrinolysis (1992) (26)
Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. (1981) (25)
Role of plasminogen activation in neuronal organization and survival (2009) (25)
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. (1994) (24)
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. (2012) (23)
Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific Monoclonal Antibody Directed against Human Fibrin and against Urokinase-Type Plasminogen Activator (1991) (23)
Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin. (1992) (23)
Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI) (1990) (23)
Influence of membrane‐bound tumor necrosis factor (TNF)‐α on obesity and glucose metabolism (2004) (23)
Towards better thrombolytic therapy. (1991) (22)
Modulation of Cell-associated Plasminogen Activation by Stromelysin-1 (MMP-3) (1999) (22)
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface. (1999) (22)
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen (1996) (22)
Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator. (1988) (21)
Macrophage elastase (MMP-12) in expanding murine adipose tissue. (2013) (21)
Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma (1991) (20)
Small Animal Thrombosis Models for the Evaluation of Thrombolytic Agents (1991) (20)
α2-Antiplasmin Gene Deficiency in Mice Does Not Affect Neointima Formation After Vascular Injury (2000) (20)
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. (1992) (19)
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity. (2001) (19)
Effect of gelatinase inhibition on adipogenesis and adipose tissue development (2012) (19)
Staphylokinase, a fibrin-specific bacterial plasminogen activator (1996) (19)
Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activator. (1987) (19)
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons (1992) (19)
Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. (2011) (18)
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. (1990) (18)
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. (1995) (18)
Effect of premature aging on murine adipose tissue (2012) (17)
On the future of thrombolytic therapy for acute myocardial infarction. (1993) (17)
Molecular mechanisms of thrombolytic therapy. (1986) (17)
Role of Thrombospondin‐2 in Murine Adipose Tissue Angiogenesis and Development (2012) (17)
Procoagulant Properties of Intravenous Staphylokinase Versus Tissue-Type Plasminogen Activator (1996) (17)
Molecular interactions between tissue-type plasminogen activator and plasminogen. (1993) (16)
Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors (1982) (16)
Protease inhibitors of human plasma. Alpha-2-antiplasmin. (1985) (16)
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex. (1998) (16)
Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice (2009) (15)
Recent developments in thrombolytic therapy (2000) (15)
Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin (1982) (15)
Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. Introduction. (1993) (15)
Deficiency of Bmal1 disrupts the diurnal rhythm of haemostasis (2019) (14)
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase. (1985) (14)
Tissue-type Plasminogen Activator (tPA) Interacts with Urokinase-type Plasminogen Activator (uPA) via tPA's Lysine Binding Site (1995) (14)
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. (1991) (14)
On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin. (1992) (14)
Effect of Standard and Low-Molecular Weight Heparin Fractions on Fibrinolysis and Platelet Aggregation in Patients Undergoing Hysterectomy (1986) (13)
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator. (2000) (13)
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). (2001) (12)
Properties of staphylokinase and its potential as a thrombolytic agent (1995) (12)
Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator. (1984) (12)
Characterisation of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising Leu144 through Leu411) and F(ab′)2-fragments of a fibrin D-dimer-specific monoclonal antibody (1990) (12)
Molecular mechanisms of thrombolysis: implications for therapy. (1990) (12)
Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line (1992) (12)
Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice (2012) (12)
Effect of fumagillin on adipocyte differentiation and adipogenesis. (2010) (11)
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase. (1992) (11)
Characterisation of a mutant of recombinant human single chain urokinase-type plasminogen activator (scu-PA), obtained by substitution of arginine 156 and lysine 158 with threonine (1988) (11)
New strategies in the development of thrombolytic agents. (1988) (11)
Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type-1 (TIMP-1) (1998) (11)
Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin. (1981) (11)
Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11) (1998) (10)
Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma (1993) (10)
Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers. (2009) (10)
Enzymatic properties of phage-displayed fragments of human plasminogen. (1997) (10)
Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator. (1988) (10)
Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1990) (9)
A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induces a modification of its functional properties (1997) (9)
On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen. (1990) (9)
Molecular mechanism of fibrinolysis. (1984) (9)
Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment. (1989) (9)
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase. (1992) (9)
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis (2010) (9)
Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin (1981) (8)
Turnover of histidine-rich glycoprotein during heparin administration in man. (1983) (8)
Screening panels of monoclonal antibodies using phage-displayed antigen. (1997) (8)
Interactions of Staphylokinase with Human Platelets (1995) (8)
Differential Inhibition with Antifibrinolytic Agents of Staphylokinase and Streptokinase Induced Clot Lysis (1995) (8)
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. (1992) (8)
A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis. (1986) (8)
Binding of streptokinase and staphylokinase to plasminogen (1995) (8)
Expression and Characterization of Clustered Charge-to-Alanine Mutants of Low Mr Single-Chain Urokinase-Type Plasminogen Activator (1994) (7)
Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of the SSC Fibrinolysis Subcommittee 1990. (1990) (7)
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator. (1990) (7)
TOWARDS THE DEVELOPMENT OF IMPKOVED THROMBOLYTIC AGENTS (1991) (7)
Development of thrombolytic agents. (1993) (7)
Amino-acid sequence of human alpha 2-antiplasmin. (1987) (6)
Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis (1991) (6)
On the role of placental growth factor in murine adipogenesis. (2007) (6)
Plasminogen Binding Properties of Macrophage Inflammatory Protein (MIP)-2α (2000) (6)
Kinetics of the Inhibition of Plasmin in Acidified Human Plasma (1982) (6)
The reaction of azide with Limulus polyphemus methaemocyanin (1978) (6)
Amino-acid sequence of human a2-antiplasmin (1987) (6)
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala. (1992) (5)
Primary Structure of Human a2-Antiplasmin, a Serine Protease Inhibitor (Serpin)* (2001) (5)
Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160 (1990) (5)
Remaining Perspectives of Mutant and Chimeric Plasminogen Activators (1992) (4)
Biochemical and biological properties of single-chain urokinase-type plasminogen activator. (1986) (4)
Thrombolytic therapy. (1991) (4)
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. (1995) (4)
A FUSION PROTEIN OF THE A-CHAIN OF t-PA WITH LOW Mr scu-PA COMBINES THE FIBRIN-SPECIFICITY OF BOTH MOLECULES (1987) (4)
Purification and partial primary structure of cyanogen bromide fragments from human α2-antiplasmin (1982) (4)
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160. (1988) (3)
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. (1994) (3)
Bio-Immunoassay for Staphylokinase in Blood (1993) (3)
Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH2-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator (1988) (3)
Functional interactions between pancreatic beta cells and (pre)adipocytes (2010) (3)
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. (1992) (3)
New thrombolytic agents and strategies. (1995) (3)
[Tissue plasminogen activator: mechanism of action and thrombolytic properties]. (1986) (3)
Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin. (1985) (3)
Chapter 8 Fibrinolysis and thrombolysis (1986) (2)
Tissue-type plasminogen activator: helping patients with acute myocardial infarction (2001) (2)
Correlation between progressive adsorption of plasminogen to blood clots immersed in a plasma milieu and clot sensitivity to lysis (1990) (2)
Corrigendum to “Effect of premature ageing on murine adipose tissue” [Experimental Gerontology (2012) 256–262] (2012) (2)
Functional Properties of p-Anisoylated Plasmin-Staphylokinase Complex (1993) (2)
A SENSITIVE BIOINALNOASSAY (BIAS) FOR TISSUE PLASMINOGEN ACTIVATOR IN PLASMA: A REPLACEMENT FOR THE EUGLOBULIN CLOT LYSIS TIME (ECLT) ASSAY (1988) (2)
Partial Primary Structure Of Human α2-Antiplasmin (1981) (2)
Combination of animal models and biotechnologies in the development of new thrombolytic agents (1993) (2)
Laboratory Investigation Thrombolytic andPharmacokinetic Properties ofaConjugate ofRecombinant Single-Chain Urokinase-Type Plasminogen Activator WithaMonoclonal Antibody Specific forCross-Linked Fibrin ina BaboonVenousThrombosis Model (1990) (2)
PROPERTIES OF A HUMAN RECOMBINANT FUSION PROTEIN OF THE ‘FINGER’ DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND A TRUNCATED SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA) (1987) (2)
282 Functional properties of chimaeric molecules containing structural domains of tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA) (1988) (2)
Haemostasis (1997) (2)
Basic Aspects of Fibrinolysis and Thrombolysis (2002) (1)
Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis* (1996) (1)
Decreased Reactivity of Plasmin-Streptokinase Towards α-2-Antiplasmin (1979) (1)
Characterisation of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site (1992) (1)
Fibrin-specific Clot Lysis with Single Chain Urokinase-type Plasminogen Activator (scu-PA) (1990) (1)
PROTEINASE INHIBITORS | Alpha-2 Antiplasmin (2006) (1)
[Molecular mechanisms of thrombolytic therapy]. (1986) (1)
Chromogenic substrate assays of components of the fibrinolytic system. (1982) (1)
Amidolytic determination of Factor X in clinical plasma samples. (1983) (1)
Extrinsic plasminogen activator: a new principle in fibrinolysis. (1983) (1)
-Induced Abdominal Sepsis in Mice coli Escherichia Activator Is Protective during Endogenous Tissue-Type Plasminogen (2006) (1)
The effect of retraction on the clot sensitivity to lysis (1990) (1)
New strategies in the development of thrombolytic agents (1988) (1)
Mechanism of action and thrombolytic potential of staphylokinase. (1995) (1)
Plasminogen Activator Isoenzymes in Breast Tumours (1986) (0)
Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasmin. (1982) (0)
Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis 1 (2006) (0)
infusion activator to fibrin: useful to monitor fibrinogen breakdown during t-PA A monoclonal antibody preventing binding of tissue-type plasminogen (2011) (0)
Irish association for cancer research Proceedings of 23rd Annual Meeting held in Cork, May, 1966 (1987) (0)
Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet. (2006) (0)
Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
Progress in the pharmacology of thrombolytic agents (1992) (0)
Bernd Binder (January 7, 1945 – August 28, 2010) (2010) (0)
CHARACTERIZATION OFα2-ANTIPLASMIN.REACTIVE SITE VARIANTS PRODUCED BY SITE-DIRECTED MUTAGENESIS (1987) (0)
Vascular and cellular proteolytic activity in mice with α2-antiplasmin gene inactivation (2000) (0)
Molecular Regulation of Fibrinolysis (1997) (0)
Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
Fibrin(ogen) degradation by a 24k-endopeptidase from a Chryseobacterium Sp. (2000) (0)
Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments (1991) (0)
Effect of Vioxx on adipose tissue development in mice with genetically determined obesity (2008) (0)
Scientific and Standardization Committee Communications Recommendations for the Nomenclature of Mutant Fibrinolytic Genes and Their Proteins (1990) (0)
plasma clot lysis with single-chain urokinase-type plasminogen activator in plasminogen activator. Application to the study of the mechanism of A monoclonal antibody specific for two-chain urokinase-type (2011) (0)
Chromogenic substrate assays: mechanism, specificity and application in blood coagulation and fibrinolysis. (1983) (0)
Mouse Genetic Models in Studying Adipose Angiogenesis (2013) (0)
Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-12 of α2-antiplasmin (fibrin cross-linking site) and amino aids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator (1992) (0)
Welcome Address by Prof. A. Serradimigni (1986) (0)
Plasmin-lnduced Platelet Activation and Disaggregation (2018) (0)
Contributions of biotechnology to thrombolytic therapy (1992) (0)
PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version (1998) (0)
Biochemical, Thrombolytic and Pharmacokinetic Properties of rt-PA P47G, K49N, a Substitution Variant of Human Tissue-Type Plasminogen Activator (1992) (0)
Contents Vol. 33 (2003) (0)
Structure-function relationships in staphylokinase as revealed by “clusteredcharge-to-alanine” mutagenesis (1994) (0)
Chapter 6 Explanations for coagulation activation after air travel (2009) (0)
therapeutic potential? Staphylokinase, a fibrin-specific plasminogen activator with (2011) (0)
[Mechanism of action of heparin]. (1986) (0)
in a hamster pulmonary embolism model continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator Comparative thrombolytic properties of bolus injections and (2011) (0)
Role of ADAMTS5 in non-alcoholic steatohepatitis (2018) (0)
AN ALANINE INSERTION IN α2-ANTIPLASMIN ‘ENSCHEDE’ ABOLISHES ITS PLASM IN INHIBITORY ACTIVITY (1987) (0)
Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD (2002) (0)
mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 ) (2003) (0)
Extracellular proteolysis in development and progression of atherosclerosis (2002) (0)
Pathophysiology of fibrinolysis (1994) (0)
History of Discovery The Tissue-Type Plasminogen Activator Story (2009) (0)
Intramolecular domain-domain interactions in tPA and tPA/Uk chimeric molecules (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With H. Roger Lijnen?

H. Roger Lijnen is affiliated with the following schools:

KU Leuven

H. Roger Lijnen's Academic­Influence.com Rankings

Why Is H. Roger Lijnen Influential?

H. Roger Lijnen's Published Works

Published Works

What Schools Are Affiliated With H. Roger Lijnen?

H. Roger Lijnen's AcademicInfluence.com Rankings